Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Cancer rates soar in China:

This article was originally published in Clinica

Executive Summary

Cancer was the leading cause of death in China during 2006, according to a health ministry report. A recent survey of 30 cities and 78 counties reports a 19% rise in fatalities in urban areas and 23% in rural areas, but exact incidence rates are not provided, according to the Chinese Center for Disease Control and Prevention (CDC). Environmental pollution, particularly of air and water, but also of livestock, is considered to be responsible. For example, air pollution from formaldehyde used in household work and furniture "is a major cause of lung cancers", says the CDC. The disease has been devastating villages, leading to frequent use of the term "cancer villages" in official reports. After cancer, the biggest killers are cerebrovascular diseases, followed by heart and respiratory ailments.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT048896

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel